Skip to main content
  • Register
  • Help
  • Contact us

Merus NV (MRUS) EUR0.05

Sell:$22.54 Buy:$23.49 Change: $0.38 (1.65%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$22.54
Buy:$23.49
Change: $0.38 (1.65%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$22.54
Buy:$23.49
Change: $0.38 (1.65%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.

Contact details

Address:
Yalelaan 62
UTRECHT
3584 CM
Netherlands
Telephone:
+31 (30) 2538800
Website:
https://www.merus.nl/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MRUS
ISIN:
NL0011606264
Market cap:
$842.61 million
Shares in issue:
38.13 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Netherlands
Currency:
US dollar
Indices:
n/a

Key personnel

  • Sven Lundberg
    President, Chief Executive Officer, Principal Financial Officer, Executive Director
  • John de Kruif
    Chief Technology Officer
  • Peter Silverman
    General Counsel, Chief Intellectual Property Officer and Head of US Legal
  • Alexander Bakker
    Chief Development Officer
  • Andrew Joe
    Chief Medical Officer
  • Hui Liu
    Chief Business Officer and Head of Merus U.S.

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.